Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a Chemo-Free combo beat HER2 breast cancer?

NCT ID NCT04733118

First seen Nov 20, 2025 · Last updated Apr 29, 2026 · Updated 23 times

Summary

This study tests whether a chemotherapy-free combination of drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer. About 393 adults with early-stage disease will receive these drugs before surgery to see if the cancer disappears completely. The goal is to find a less toxic treatment option that still prevents the cancer from coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • AO Ospedale Civile Legnano

    Milan, Italy

  • Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola-Malpighi

    Bologna, Italy

  • Azienda Ospedaliero-Universitaria di Parma

    Parma, Italy

  • Békés county hospital

    Békés, Hungary

  • Centro Oncológico de Galicia

    A Coruña, 15009, Spain

  • Complejo Asistencial Universitario de León

    León, Spain

  • Complejo Hospitalario de Jaen

    Jaén, Spain

  • Consorcio Hospital General de Valencia

    Valencia, Spain

  • Consorcio Hospitalario Provincial De Castelló

    Castellon, 12002, Spain

  • Evangelisches Krankenhaus Bethesda

    Duisburg, Germany

  • Fondazione Policlinico Universitario Agostino Gemelli

    Roma, Italy

  • Hospital Arnau de Vilanova de Valencia

    Valencia, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, Spain

  • Hospital Clínico San Carlos

    Madrid, 28040, Spain

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital La Fe

    Valencia, 46026, Spain

  • Hospital Quirón San Camilo- Ruber Juan Bravo

    Madrid, Spain

  • Hospital Ramón y Cajal

    Madrid, Spain

  • Hospital Universitari Arnau de Vilanova de Lleida

    Lleida, Spain

  • Hospital Universitari Dexeus - Grupo Quirónsalud

    Barcelona, Spain

  • Hospital Universitari San Joan de Reus

    Reus, Tarragona, Spain

  • Hospital Universitario A Coruña

    A Coruña, Spain

  • Hospital Universitario Clínico San Cecilio de Granada

    Granada, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, Cordoba, 14004, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, Spain

  • Hospital Universitario de Basurto

    Bilbao, 48013, Spain

  • Hospital Universitario de Torrejón

    Torrejón, Spain

  • ICO L'Hospitalet - Instituto Catalán de Oncología

    L'Hospitalet de Llobregat, Barcelona, 08007, Spain

  • Institut Català d' Oncologia Badalona (ICO)

    Badalona, Spain

  • Instituto Valenciano de Oncología (IVO)

    Valencia, 46009, Spain

  • Istituto Europeo di Oncologia - NC

    Milan, Italy

  • Kliniken Essen Mitte

    Essen, Germany

  • Klinikum Ernst von Bergmann

    Potsdam, Germany

  • Ospedale Guglielmo da Saliceto

    Piacenza, Italy

  • Ospedale San Gerardo

    Monza, Italy

  • Praxisnetzwerk Hämatologie und intern. Onkologie

    Cologne, Germany

  • Tolna County Balassa János Hospital

    Szekszárd, Hungary

  • UMHAT Sveti Ivan Rilski EAD Department of Medical Oncology

    Sofia, Bulgaria

  • Universitätsklinikum Essen Frauenklinik

    Essen, Germany

  • Universitätsklinikum Mannheim GmbH

    Manheim, Germany

  • VHIO Vall d'Hebron Institute of Oncology

    Barcelona, Spain

Conditions

Explore the condition pages connected to this study.